Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
634 results about "Cytoplasmic Structure" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In cell biology, the cytoplasm is the material within a living cell, excluding the cell nucleus. It comprises cytosol (the gel-like substance enclosed within the cell membrane) and the organelles – the cell's internal sub-structures.
Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
InactiveUS6881825B1Reduce deliveryFacilitating uptakeCompound screeningApoptosis detectionIn vivoCell type
The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of the peptides, and methods of use for the peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro.
Owner:UNIVERSITY OF PITTSBURGH
Chimeric receptor genes and cells transformed therewith
Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
Owner:UNITED STATES OF AMERICA +1
Chimeric receptors with 4-1BB stimulatory signaling domain
InactiveUS20050113564A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsT cell
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. Also included is a method for obtaining an enriched population of NK cells from a mixed population of NK cells and T cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
Owner:UNIVERSITY OF PITTSBURGH
Gene silencing methods
InactiveUS6531647B1Sugar derivativesOther foreign material introduction processesWhole bodyGene silencing
Disclosed are methods for silencing a target nucleotide sequence (preferably representing one or more endogenous genes, preferably in a systemic fashion) which is present in a first part of the plant, which method comprises transiently introducing into the cytoplasm of a cell in a second part of the plant, which cell comprises a nucleic acid encoding the target sequence and which is remote from said first part of the plant, a nucleic acid construct.
Owner:PLANT BIOSCI LTD
Pluripotent stem cells derived without the use of embryos or fetal tissue
InactiveUS20030113910A1New breed animal cellsArtificial cell constructsPluripotential stem cellGerm layer
Owner:STEMA
Chloroquine coupled antibodies and other proteins with methods for their synthesis
InactiveUS20070166281A1Improve efficacyImprove transportBiocidePeptide/protein ingredientsDrug conjugationTreatment effect
This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the drug is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a drug directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing the drug for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and antibody or insulin to their site of action.
Owner:KOSAK KENNETH M
Nanoparticle delivery vehicle
A nanoparticle delivery vehicle, comprising a nanoparticle, an active agent and a nuclear localization signal and methods of modulating gene expression and protein expression employing the nanoparticle delivery vehicle. A representative method includes providing a nanoparticle delivery vehicle comprising a nanoparticle having a diameter of about 30 nm or less, an active agent and a nuclear localization signal; and contacting a target cell with the nanoparticle delivery vehicle, whereby an active agent is delivered to the nucleus of a target cell. Another representative method includes providing a nanoparticle delivery vehicle comprising a nanoparticle having a diameter greater than or equal to about 30 nm, an active agent and a nuclear localization signal; and contacting a target cell with the nanoparticle delivery vehicle, whereby an active agent is delivered to the cytoplasm of a cell.
Owner:NORTH CAROLINA STATE UNIV
Systems and methods for treating, diagnosing and predicting the occurence of a medical condition
InactiveUS20070099219A1Medical simulationMicrobiological testing/measurementAbnormal tissue growthBiopsy
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including seminal vesicle involvement, surgical margin involvement, lymph node status, androgen receptor (AR) staining index of tumor, a morphometric measurement of epithelial nuclei, and at least one morphometric measurement of stroma. In another embodiment, a model that predicts clinical failure post prostatectomy is provided, wherein the model is based on features including biopsy Gleason score, lymph node involvement, prostatectomy Gleason score, a morphometric measurement of epithelial cytoplasm, a morphometric measurement of epithelial nuclei, a morphometric measurement of stroma, and intensity of androgen receptor (AR) in racemase (AMACR)-positive epithelial cells.
Owner:AUREON LAB INC +2
Systems and methods for treating diagnosing and predicting the occurrence of a medical condition
InactiveUS20100088264A1Medical automated diagnosisKnowledge representationGleason gradeComputer generation
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all) of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR− epithelial nuclei.
Owner:AUREON LAB INC +1
Method and system for digital image based tissue independent simultaneous nucleus cytoplasm and membrane quantitation
A method and system for automatic digital image based tissue independent simultaneous nucleus, cytoplasm and membrane quantitation. Plural types of pixels comprising cell components including at least cell cytoplasm and cell membranes from a biological tissue sample to which a chemical compound has been applied and has been processed to remove background pixels and pixels including counterstained components are simultaneously identified. The identified cell components pixels are automatically classified to determine a medical conclusion such as a human breast cancer, a human prostrate cancer or an animal cancer.
Owner:VENTANA MEDICAL SYST INC
Microbial detection and quantification
InactiveUS20060134728A1Increase brightnessGood colorBioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismCell membrane
A method for semi-quantitatively or quantitatively detecting the presence of a microbe in a sample is provided. The method utilizes a test dye that undergoes a detectable color change in the presence of one or more microbes. For example, in one embodiment, the test dye is a solvatochromic dye (e.g., Reichardt's dye) that responds to differences in polarity between microbe components (e.g., cell membrane, cytoplasm, etc.) and the environment outside the cell. Alternatively, other mechanisms may be wholly or partially responsible for the interaction between the dye and the microbe, such as acid-base reactions, redox reactions, and so forth. Regardless, the color of the test dye may be compared to the color of a control dye, wherein the color of the control dye corresponds to a known microbe concentration.
Owner:KIMBERLY-CLARK WORLDWIDE INC
Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) a readily oxidizable chemical group for exerting antioxidation properties; and (c) a chemical make-up for permitting the compound or its intracellular derivative to accumulate within the cytoplasm of cells.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1
Chimeric receptor genes and cells transformed therewith
InactiveUS20120093842A1Limit acquisitionVirusesPeptide/protein ingredientsTherapeutic treatmentReceptor for activated C kinase 1
Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
Owner:CABARET BIOTECH
Production of a transgenic avian by cytoplasmic injection
InactiveUS20030126629A1Promote absorptionImprove efficiencyVirusesNucleic acid vectorEmbryoTransgene
This invention provides methods for the stable introduction of heterologous coding sequences into the genome of a bird and expressing the coding sequences to produce desired proteins or to alter the phenotype of the bird. The present invention provides preferred methods for introducing a transgene into the cytoplasm of avian embryonic cells by cytoplasmic microinjection. The embryo then develops into a transgenic adult capable of expressing a heterologous protein and / or capable of generating a line of transgenic birds through breeding. Synthetic vectors and gene promoters useful in the methods are also provided by the present invention, as are transgenic birds that express heterologous protein and avian eggs containing heterologous protein.
Owner:SYNAGEVA BIOPHARMA CORP
Method and apparatus for automatically recognizing blood cells
InactiveUS6330350B1Biological particle analysisAcquiring/recognising microscopic objectsRed blood cellCell feature
A method and apparatus for automatically recognizing blood cells is provided. The method comprises obtaining image data of said blood cells, storing the image data of said blood cells in a memory, analyzing the image data of said blood cells and calculating a plurality of cell-characteristic parameter values for each of said blood cells, and recognizing each of said blood cells based on said plurality of cell-characteristic parameter values. In order to analyze the image data of blood cells, a group of nucleus pixels are first extracted from said stored image data and stored in the memory. The group of nucleus pixels are then segmented into individual nucleus clusters which represent each of the blood cells, and the data of the individual nucleus clusters are stored together with the associated cytoplasm data in the memory. Cell-characteristic parameter values for each of the blood cells are calculated based on its nucleus and associated cytoplasm data. The cell-characteristic parameter values are used in recognizing the blood cells.
Owner:KOREA INST OF SCI & TECH
Detection of microbe contamination on elastomeric articles
ActiveUS20060134613A1Bioreactor/fermenter combinationsBiological substance pretreatmentsMicroorganismOxidation-Reduction Agent
An elastomeric article that contains a chromogen that undergoes a detectable change in color in the presence of one or more microbes is provided. For example, in one embodiment, the chromogen is a solvatochromic dye (e.g., Reichardt's dye) that undergoes a color change in the presence of bacteria or other microbes. More specifically, such dyes may respond to differences in polarity between microbe components (e.g., cell membrane, cytoplasm, etc.) and the environment outside the cell. Alternatively, other mechanisms may be wholly or partially responsible for the interaction between the dye and the microbe, such as acid-base reactions, redox reactions, and so forth.
Owner:O&M HALYARD INC
Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
InactiveCN101689220AMedical automated diagnosisSpecial data processing applicationsGleason gradeBiopsy
Methods and systems are provided that use clinical information, molecular information and computer-generated morphometric information in a predictive model for predicting the occurrence (e.g., recurrence) of a medical condition, for example, cancer. In an embodiment, a model that predicts prostate cancer recurrence is provided, where the model is based on features including one or more (e.g., all)of biopsy Gleason score, seminal vesicle invasion, extracapsular extension, preoperative PSA, dominant prostatectomy Gleason grade, the relative area of AR+ epithelial nuclei, a morphometric measurement of epithelial nuclei, and a morphometric measurement of epithelial cytoplasm. In another embodiment, a model that predicts clinical failure post-prostatectomy is provided, wherein the model is based on features including one or more (e.g., all) of dominant prostatectomy Gleason grade, lymph node invasion status, one or more morphometric measurements of lumen, a morphometric measurement of cytoplasm, and average intensity of AR in AR+ / AMACR- epithelial nuclei.
Owner:AUREON LAB INC
Plants resistant to cytoplasm-feeding parasites
ActiveUS20070199100A1Increase productionImprove plant resistanceSugar derivativesClimate change adaptationCytoplasmic StructureGMO Plants
The present invention relates to transgenic plants resistant to parasites that their normal life cycle includes feeding on the plant cytoplasm, including insects, nematodes and fungi, wherein the plants are engineered to produce small interfering RNAs (siRNAs) capable of silencing a parasite specific gene. Particularly the parasite gene is a stage-specific gene, more particularly a gene involved in essential, early developmental stages of the parasite in or on the plant.
Owner:BAR ILAN UNIV +3
Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
Owner:AUREON LAB INC +2
Method and device for classifying white blood cells
ActiveCN103745210AAccurate classificationCharacter and pattern recognitionMaterial analysisWhite blood cellSample image
The invention provides a method and a device for classifying white blood cells. The method comprises the following steps: dyeing the white blood cells in a blood sample to obtain a blood sample containing the dyed white blood cells; performing image acquisition on the white blood cell blood sample to obtain a white blood cell blood sample image; segmenting various cells of the white blood cell blood sample image, and respectively extracting cell morphology characteristic parameters of various cells; performing re-segmentation on various segmented cells to obtain a cell nucleus image and a cytoplasm and particle image; extracting color characteristic parameters of the cell nucleus image; extracting particle distribution characteristic parameters and color characteristic parameters of the cytoplasm and particle image; performing normalization on extracted characteristics; sending the normalized characteristics into a neural network classifier, identifying five types of cells in the white blood cells, and respectively working out the number of the five types of cells and the percentage of total white blood cell count. According to the method and the device for classifying the white blood cells provided by the invention, the white blood cells can be accurately classified.
Owner:AVE SCI & TECH CO LTD
Non-invasive prenatal genetic diagnosis using transcervical cells
InactiveUS20050181429A1Microbiological testing/measurementDisease diagnosisPrenatal diagnosisStaining
A non-invasive, risk-free method of prenatal diagnosis is provided. According to the method of the present invention transcervical specimens are subjected to trophoblast-specific immuno-staining followed by FISH, PRINS, Q-FISH and / or MCB analyses and / or other DNA-based genetic analysis in order to determine fetal gender and / or identify chromosomal and / or DNA abnormalities in a fetus. Also provided is a method of in situ chromosomal, DNA and / or RNA analysis of a prestained specimen by incubating the prestained specimen in ammonium hydroxide. Also provided is a method of identifying embryonic cells according to a nucleus / cytoplasm ratio of at least 1:1 and the presence of at least variably condensed chromatin.
Owner:MONALIZA MEDICAL
Bacterial vectors and methods of use thereof
InactiveUS7390646B2Bacterial antigen ingredientsSsRNA viruses positive-senseImmunogenicityGene expression
Owner:RGT UNIV OF CALIFORNIA
Method and system for digital image based tissue independent simultaneous nucleus cytoplasm and membrane quantitation
A method and system for automatic digital image based tissue independent simultaneous nucleus, cytoplasm and membrane quantitation. Plural types of pixels comprising cell components including at least cell cytoplasm and cell membranes from a biological tissue sample to which a chemical compound has been applied and has been processed to remove background pixels and pixels including counterstained components are simultaneously identified. The identified cell components pixels are automatically classified to determine a medical conclusion such as a human breast cancer, a human prostrate cancer or an animal cancer.
Owner:VENTANA MEDICAL SYST INC
Chemical address tags
The present invention provides methods and compositions related to the fields of chemoinformatics, chemogenomics, drug discovery and development, and drug targeting. In particular, the present invention provides subcellular localization signals (e.g., chemical address tags) that influence (e.g., direct) subcellular and organelle level localization of associated compounds (e.g., drugs and small molecule therapeutics, radioactive species, dyes and imagining agents, proapoptotic agents, antibiotics, etc) in target cells and tissues. The compositions of the present invention modulate the pharmacological profiles of associated compounds by influencing the compound's accumulation, or exclusion, from subcellular loci such as mitochondria, endoplasmic reticulum, cytoplasm, vesicles, granules, nuclei and nucleoli and other subcellular organelles and compartments. The present invention also provides methods for identifying chemical address tags, predicting their targeting characteristics, and for rational designing chemical libraries comprising chemical address tags.
Owner:RGT UNIV OF MICHIGAN
Chloroquine combination drugs and methods for their synthesis
InactiveUS20070060499A1Facilitated releaseReduce needBiocideGenetic material ingredientsActive agentSynthesis methods
This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.
Owner:KOSAK KENNETH M
Method for segmenting cervix uteri liquid base cell image
ActiveCN102831607ASegmentation is reliable and preciseOvercome lighting changesImage enhancementImage analysisPattern recognitionCervix
The invention discloses a method for segmenting a cervix uteri liquid base cell image. The method comprises the following steps of: 1, cell segmentation: performing illumination correction on an image, filtering noises and enhancing a cell boundary; and dividing the image into three types of cytoplasm, nucleus and background to eliminate a background class area; 2, nucleus segmentation: detecting centers of each of nucleuses in the cell area, estimating the approximate shapes of the nucleuses close to the centers of the nucleuses and correcting the shapes of the nucleuses to acquire an accurate boundary. The method is applied to cervix uteri cells and cell masses in a wide vision range, so that the phenomena of changed illumination, non-uniform dyeing and noise influence to a certain extent are avoided, and the cytoplasm, the single nucleus and adhesion nucleus can be segmented reliably and accurately.
Owner:SHENZHEN MICRO BIOLOGICAL TECH CO LTD
Exfoliative cells preserving fluid
InactiveCN103120153AHigh transparencyClear boundariesDead animal preservationHuman papillomavirusProduction effect
The invention discloses an exfoliative cells preserving fluid which is prepared from a pH buffering agent, an osmotic pressure maintenance agent, preservatives, a fixing agent for maintaining cellular morphology, an anticoagulant, a mucus softener, an antimicrobial reagent, a cleaning agent, a humectant and red blood cell destroying components. The components in the preserving fluid are reasonable in proportioning, and the exfoliative cells can be preserved at a long time under normal temperature, wherein the longest time can reach 2 years; mucus can be sufficiently dissolved and the red cells can be partially destroyed; a film production effect is good, cellular distribution is very even, cellular morphology is perfect, cytoplasm and cell nucleus demarcation is distinct, gradation is clear, and cytoplasm and cell nucleus transparency is very good, and the exfoliative cells preserving fluid can be simultaneously used for the HPV-DNA (human papillomavirus-deoxyribonucleic acid), Chlamydia and immunohistochemical test; the special liquid base preserving fluid used for the cytologic examination of other parts can be provided, an imported product can be completely replaced, and the cellular constituent with diagnostic significance can be sufficiently preserved; and the exfoliative cells preserving fluid is low in configuration cost and easy to popularize.
Owner:刘召宏
Microscope system and screening method for drugs, physical therapies and biohazards
InactiveUS20090081775A1Image analysis becomes easy and reliableMinimized cell clusteringAntibacterial agentsCompound screeningFluorescenceScreening method
Method and device for automated cell analysis and determination of transport and communication between living cells by analyzing the formation of tunneling nanotubes (TNTs) between cells. This method comprising the steps of singularizing cells in a culture medium and staining the cells with a fluorescent or luminescent dyes for staining of cytoplasm and membranes as well as TNTs, flagella and other cell particles for 3-D cell microscopy. The method comprises further an image analysis system.
Owner:STIFTELSEN UNIVTSFORSKNING BERGEN
Non-viral delivery of compounds to mitochondria
ActiveUS20050169904A1Effective treatmentBiocidePeptide/protein ingredientsActive agentMitochondrial protein
A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described.
Owner:WAKE FOREST UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com